It has been reported that down‐regulation of PRMT5 by RNAi prevented cancer cell proliferation and cell cycle transition through PI3K/Akt signalling pathway3 and a large number of corroborating studies have shown that PRMT5 expression level was significantly elevated in various cancers, including gastric,4 colorectal,5 lung,3 lymphoma,6 leukaemia7 and liver8 cancers. This evidence concerns the gene PRMT5 and lymphoma.